Three cases of Creutzfeldt-Jakob disease presenting with a predominant dysexecutive syndrome.
Three cases of Creutzfeldt-Jakob disease presenting with a predominant dysexecutive syndrome.
复制标题
DOI:
10.1007/s00415-022-11045-7
复制
发表时间:
2022-08
影响因子:
6
通讯作者:
Jones DT
中科院分区:
文献类型:
--
作者:
Corriveau-Lecavalier N;Li W;Ramanan VK;Drubach DA;Day GS;Jones DT
Creutzfeldt-Jakob disease (CJD) is a rare, uniformly fatal prion disease. Although CJD commonly presents with rapidly progressive dementia, ataxia, and myoclonus, substantial clinicopathological heterogeneity is observed in clinical practice. Unusual and predominantly cognitive clinical manifestations of CJD mimicking common dementia syndromes are known to pose as an obstacle to early diagnosis and prognosis. We report a series of three patients with probable or definite CJD (one male and two females, ages 52, 58 and 68) who presented to our tertiary behavioral neurology clinic at Mayo Clinic Rochester that met criteria for a newly defined progressive dysexecutive syndrome. Glucose hypometabolism patterns assessed by 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) strongly resembled those of dysexecutive variant of Alzheimer’s disease (dAD). However, magnetic resonance imaging (MRI) demonstrated restricted diffusion in neocortical areas and deep nuclei, while cerebrospinal fluid biomarkers indicated abnormal levels of 14-3-3, total-tau, and prion seeding activity (RT-QuIC), establishing the diagnosis of CJD. Electroencephalogram (EEG) additionally revealed features previously documented in atypical cases of CJD. This series of clinical cases demonstrates that CJD can present with a predominantly dysexecutive syndrome and FDG-PET hypometabolism typically seen in dAD. This prompts for the need to integrate information on clinical course with multimodal imaging and fluid biomarkers to provide a precise etiology for dementia syndromes. This has important clinical implications for the diagnosis and prognosis of CJD in the context of emerging clinical characterization of progressive dysexecutive syndromes in neurogenerative diseases like dAD.
登录
查看更多内容
影响因子:
5.1
作者:
Kim EJ;Cho SS;Jeong BH;Kim YS;Seo SW;Na DL;Geschwind MD;Jeong Y
通讯作者:
Jeong Y
DOI:
10.1016/s1474-4422(20)30440-3
发表时间:
2021-03
期刊:
The Lancet. Neurology
影响因子:
--
作者:
Graff-Radford J;Yong KXX;Apostolova LG;Bouwman FH;Carrillo M;Dickerson BC;Rabinovici GD;Schott JM;Jones DT;Murray ME
通讯作者:
Murray ME
影响因子:
4.7
作者:
Cambier, DM;Kantarci, K;Aksamit, AJ
通讯作者:
Aksamit, AJ
影响因子:
14.5
作者:
Kapur, N;Abbott, P;Will, RG
通讯作者:
Will, RG
影响因子:
2.4
作者:
Orimo, S;Ozawa, E;Mizusawa, H
通讯作者:
Mizusawa, H